CHICAGO and CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that AP23573 – its novel mTOR inhibitor – demonstrated efficacy and was well tolerated as a single agent in a multi-center Phase 2 trial in metastatic endometrial cancer involving 45 patients, all of whom had progressive disease. The primary end-point of the trial – evidenced by significant clinical-benefit response (CBR) rates – was achieved. Twenty-nine percent (29%) of patients had a CBR – tumor regression or disease stabilization – including 10% with partial responses.
